Hyperimmunoglobulinemia D following cancer chemotherapy.
Five classes of serum immunoglobulin levels were investigated in 107 children with malignant or benign tumors. Hyperimmunoglobulinemia D (hyper-IgD) was observed in 31 of 82 children who were in complete remission off chemotherapy with a median follow-up of 4.5 years after cessation of chemotherapy. On the other hand, hyper-IgD was not found among 12 children with malignant or benign tumors treated with chemotherapy and a low incidence of hyper-IgD was observed during chemotherapy (1 of 13 cases). The result indicates that hyper-IgD is not uncommon in children off chemotherapy, suggesting that dysregulation of IgD synthesis persists long after cessation of antineoplastic drugs.
Azuma
E
E
Department of Pediatrics, Mie University School of Medicine, Japan.
Masuda
S
S
Hanada
M
M
Zhou
Y W
YW
Zhang
S L
SL
Shibata
T
T
Komada
Y
Y
Sakurai
M
M
D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D005260:Female; D006801:Humans; D006942:Hypergammaglobulinemia / Q000139:chemically induced*; D007072:Immunoglobulin D; D008297:Male; D013997:Time Factors
D000970:Antineoplastic Agents; D007072:Immunoglobulin D